Kohtaro Fujihashi Selected Research

Secretory Immunoglobulin A (SIgA)

1/2021	Impaired salivary SIgA antibodies elicit oral dysbiosis and subsequent induction of alveolar bone loss.
1/2019	CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.
1/2017	Rejuvenation of mucosal immunosenescence by adipose tissue-derived mesenchymal stem cells.
1/2015	Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review.
6/2014	Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly.
10/2012	Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.
1/2012	A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.
2/2011	A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.
9/2010	Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kohtaro Fujihashi Research Topics

Disease

15	Infections 11/2019 - 11/2002
5	Communicable Diseases (Infectious Diseases) 11/2021 - 07/2009
5	Human Influenza (Influenza) 10/2012 - 07/2007
4	Pneumococcal Infections 01/2018 - 02/2011
3	Diarrhea 01/2021 - 04/2004
2	Atherosclerosis 01/2022 - 06/2017
2	Cholera 01/2021 - 01/2021
2	Hypersensitivity (Allergy) 01/2021 - 02/2003
2	Inflammation (Inflammations) 01/2017 - 10/2004
2	Anthrax 02/2006 - 06/2003
1	Dental Caries (Decay, Dental) 11/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Constipation 01/2021
1	Alveolar Bone Loss 01/2021
1	Caliciviridae Infections 01/2021
1	Dysbiosis 01/2021
1	Periodontitis 01/2021
1	Periodontal Diseases (Periodontal Disease) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 06/2017
1	Bacterial Infections (Bacterial Infection) 06/2017
1	Infertility (Sterility) 01/2017
1	HIV Infections (HIV Infection) 06/2014
1	Neoplasms (Cancer) 06/2014
1	Respiratory Tract Infections (Respiratory Tract Infection) 06/2014
1	Otitis Media 01/2014
1	Pneumococcal Pneumonia 07/2011
1	Bone Resorption 06/2010
1	Alzheimer Disease (Alzheimer's Disease) 02/2007
1	Amyloid Plaque 02/2007
1	Edema (Dropsy) 02/2006
1	Botulism 02/2005
1	Duodenitis 10/2004
1	Gastritis 10/2004
1	Atrophy 03/2003
1	Wasting Syndrome (Wasting Disease) 03/2003
1	Colitis 03/2003
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2003

Drug/Important Bio-Agent (IBA)

14	VaccinesIBA 11/2021 - 06/2003
9	Secretory Immunoglobulin A (SIgA)IBA 01/2021 - 09/2010
7	AntigensIBA 01/2022 - 02/2003
6	AntibodiesIBA 01/2022 - 08/2011
6	Immunoglobulin A (IgA)IBA 01/2021 - 09/2007
5	CytokinesIBA 01/2019 - 01/2003
4	OligodeoxyribonucleotidesIBA 01/2019 - 06/2010
4	CPG-oligonucleotideIBA 01/2019 - 06/2010
4	Immunoglobulin G (IgG)IBA 01/2019 - 09/2007
4	flt3 ligand protein (flt3 ligand)IBA 06/2017 - 07/2011
3	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2019 - 11/2002
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2005
2	Phosphorylcholine (Phosphocholine)IBA 01/2022 - 08/2011
2	Oseltamivir (Tamiflu)FDA Link 10/2012 - 09/2010
2	Antiviral Agents (Antivirals)IBA 10/2012 - 09/2010
2	Neuraminidase (Sialidase)IBA 10/2012 - 09/2010
2	Proteins (Proteins, Gene)FDA Link 01/2012 - 04/2004
2	Interleukin-12 Subunit p40IBA 06/2005 - 04/2004
2	Interleukin-4 (Interleukin 4)IBA 10/2004 - 03/2003
1	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 01/2022
1	ApolipoproteinsIBA 01/2022
1	Apolipoproteins E (ApoE)IBA 01/2022
1	polyethylene glycol polyethyleneimine nanogelIBA 11/2021
1	Biocompatible Materials (Biomaterials)IBA 11/2021
1	Nonprescription Drugs (Patent Medicines)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	ChemokinesIBA 11/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2017
1	Complementary DNA (cDNA)IBA 06/2017
1	Subunit VaccinesIBA 01/2017
1	Synthetic Vaccines (Recombinant Vaccines)IBA 06/2014
1	MacrolidesIBA 10/2012
1	Clarithromycin (Biaxin)FDA LinkGeneric 10/2012
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2012
1	OvalbuminIBA 01/2012
1	FlagellinIBA 01/2012
1	Immunodominant EpitopesIBA 08/2011
1	pneumococcal surface protein AIBA 02/2011
1	Membrane Proteins (Integral Membrane Proteins)IBA 06/2010
1	alpha-galactosylceramideIBA 07/2007
1	Amyloid beta-PeptidesIBA 02/2007
1	Interleukin-10 (Interleukin 10)IBA 02/2007
1	Amyloid (Amyloid Fibrils)IBA 02/2007
1	anthrax toxin receptorsIBA 02/2006
1	Immunoglobulin E (IgE)IBA 06/2005
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2004
1	AntralIBA 10/2004
1	AluminumIBA 06/2003
1	Anthrax Vaccines (Vaccines, Anthrax)IBA 06/2003
1	Neutralizing AntibodiesIBA 06/2003
1	Recombinases (Recombinase)IBA 03/2003
1	EnzymesIBA 03/2003
1	ExotoxinsIBA 11/2002

Therapy/Procedure

1	Therapeutics 01/2021
1	Contraception (Birth Control) 01/2021
1	Immunotherapy 01/2021
1	Rectal Administration 01/2017
1	Intranasal Administration 01/2012